• Referral forms live on 97% of Australian GPs
• Telehealth service launched on EarlyDetection.com.au
• Multi-Cancer Early Detection test coming June 2026
• Sydney CBD clinic opening for high-risk patients
• Platform registered in multiple international markets

BCAL Diagnostics Limited, an Australian healthcare company focused on early cancer detection, has expanded access to its early cancer detection tests by embedding referral pathways into major GP and specialist clinical software systems. Clinical referral forms for BCAL's early detection tests are now live on Best Practice and Medical Director, two leading GP clinical software platforms that together cover approximately 97% of Australian general practitioners. In parallel, BCAL launched EarlyDetection.com.au, its telehealth service developed with Medmate, on 12 May 2026. The service provides an additional medically supported pathway for eligible patients to access BCAL's early detection tests. The EarlyDetection platform has also been registered in New Zealand, the United Kingdom, the United States, India and other international markets. The new Avantect® multi-cancer early detection test is expected to be available in the Australian market in June 2026. BCAL is also establishing a Sydney CBD high-risk early detection clinic to support patients who may benefit from medical consultation, risk assessment and access to blood-based testing.

BCAL expects to significantly expand its market reach with the new test and international registrations, aiming to address significant market opportunities.